Overview of residual cardiovascular risk
DOI:
https://doi.org/10.18041/2665-427X/ijeph.1.10357Keywords:
Cardiovascular Risk, Residual Cardiovascular Risk, HypercholesterolemiaAbstract
Cardiovascular risk is an entity that constantly climbs ranks in the Global Burden of Disease as an agent associated with morbidity and mortality.
As of today, there are guidelines that guide the management of cardiovascular risk for the prevention of associated diseases, however, once the proposed goals for risk reduction have been achieved, unwanted clinical outcomes persist, associated with the called Residual Cardiovascular Risk.
Some agents such as obesity, fatty liver, triglycerides, inflammation, thrombotic risk and metabolic risk, have been targeted for research and strengthening in order to reduce the occurrence of cardiovascular events once the proposed cardiovascular risk goals have been achieved. by international guidelines.
Currently there are some strategies such as the use of Colchicine, Rivaroxaban, Ethyl Eicosapent, PCSK9 inhibitors, among others, have shown favorable clinical outcomes associated with the reduction of residual cardiovascular risk.
Downloads
References
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1204-22. Doi: 10.1016/S0140-673620.30925-9.
Vargas-Uricoechea H, Ruiz AJ, Gómez EA, Román-González A, Castillo J, Merchán A, et al. Recomendaciones del panel de expertos sobre la fisiopatología diagnóstico y tratamiento de las dislipidemias en la población adulta.Asociación Colombiana de Endocrinología Diabetes y Metabolismo, Sociedad Colombiana de Cardiología y Cirugía Cardiovascular. Rev Colomb Endocrinol Diabetes Metab. 2020; 7: 4-36. Doi: 10.53853/encr.7.1S.573.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Cardiol. 2022; 75: 429.e1-429.e104. Doi: 10.1016/j.recesp.2021.10.016.
Castillo GA, Aroca G, Buelvas J, Buitrago AF, Carballo V, Cárdenas JM, et al. Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2. Rev Colomb Cardiol. 2020; 27: 3-22. Doi: 10.1016/j.rccar.2020.07.005.
Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011; 6(Suppl 1): 45-51. Doi: 10.1007/s11739-011-0669-5.
Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014; 13: 26. Doi: 10.1186/1475-2840-13-26.
Hernández-Mijares A, Ascaso JF, Blasco M, Brea Á, Díaz Á, Mantilla T, et al. Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos. Clínica Investig Arterioscler. 2019; 31: 75-88. Doi: 10.1016/j.arteri.2018.06.007.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22. Doi: 10.1016/S0140-673602.09327-3.
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016; 374: 2032-43. Doi: 10.1056/NEJMoa1600177.
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-407. Doi: 10.1056/NEJMoa0810177.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008; 359: 2195-207. Doi: 10.1056/NEJMoa0807646.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 4S. Lancet. 1994; 344: 1383-9.
ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-74. Doi: 10.1056/NEJMoa1001282.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-35. Doi: 10.1056/NEJMoa050461.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333: 1301-7. Doi: 10.1056/NEJM199511163332001.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-78. Doi: 10.1016/S0140-673605.67394-1.
Lu Y, Cheng Z, Zhao Y, Chang X, Chan C, Bai Y, et al. Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis. 2016; 254: 215-27. Doi: 10.1016/j.atherosclerosis.2016.10.025.
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019; 210: 18-28. Doi: 10.1016/j.ahj.2018.12.007.
Nayak A, Hayen A, Zhu L, McGeechan K, Glasziou P, Irwig L, et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open. 2018; 8: e020584. Doi: 10.1136/bmjopen-2017-020584.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335: 1001-9. Doi: 10.1056/NEJM199610033351401.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med. 2004; 350: 1495-504. Doi: 10.1056/NEJMoa040583.
Cannon CP. Low-Density Lipoprotein Cholesterol. J Am Coll Cardiol. 2020; 75: 2119-21. Doi: 10.1016/j.jacc.2020.03.033.
Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. Clin Outcomes Res CEOR. 2016; 8: 649-55. Doi: 10.2147/CEOR.S107992.
Cholesterol Treatment Trialists’ CTT. Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371: 117-25. Doi: 10.1016/S0140-673608.60104-X.
Heart Protection Study Collaborative, Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ. 2006; 333: 1145. Doi: 10.1136/bmj.38993.731725.BE.
Rodríguez-Ariza CD, Cabrera-Villamizar A, Rodríguez-Pulido AL, Callegari S, Ossa Rodríguez NA, Pinilla-Roncancio M, et al. External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort. Sci Rep. 2023; 13: 6139. Doi: 10.1038/s41598-023-32668-4.
Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med. 2002; 2: 325-33. Doi: 10.1055/s-2002-35403.
Ponte CI. Redescubriendo los triglicéridos como factor de riesgo cardiovascular. Avances Cardiol. 2009; 29(4): 367-376
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118: 547-63. Doi: 10.1161/CIRCRESAHA.115.306249.
Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51: 724-30. Doi: 10.1016/j.jacc.2007.10.038.
Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes FIELD. study. Diabetes Care. 2009; 32: 493-8. Doi: 10.2337/dc08-1543.
Bezafibrate Infarction Prevention BIP study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000; 102: 21-7. Doi: 10.1161/01.cir.102.1.21.
Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977; 55: 767-72. Doi: 10.1161/01.CIR.55.5.767.
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2014; 383: 999-1008. Doi: 10.1016/S0140-673613.61752-3.
Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-59. Doi: 10.1056/NEJMoa061894.
Bosomworth NJ. Approach to identifying and managing atherogenic dyslipidemia: A metabolic consequence of obesity and diabetes. Can Fam Physician. 2013; 59: 1169-80.
Neeland IJ, Ross R, Després J-P, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019; 7: 715-25. Doi: 10.1016/S2213-858719.30084-1.
Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, Lipoprotein (a), and inflammation. Clin Chem. 2021; 67: 143-53. Doi: 10.1093/clinchem/hvaa252.
Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. 2020; 7: 88. Doi: 10.3389/fcvm.2020.00088.
Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381: 2497-505. Doi: 10.1056/NEJMoa1912388.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61: 404-10. Doi: 10.1016/j.jacc.2012.10.027.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020; 383: 1838-47. Doi: 10.1056/NEJMoa2021372.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019; 380: 11-22. Doi: 10.1056/NEJMoa1812792.
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 219-29. Doi: 10.1016/S0140-673617.32409-1.
Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 205-18. Doi: 10.1016/S0140-673617.32458-3.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377: 1319-30. Doi: 10.1056/NEJMoa1709118.
Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51. J Am Coll Cardiol. 2013; 61: 1853-9. Doi: 10.1016/j.jacc.2013.01.066.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31: 2844-53. Doi: 10.1093/eurheartj/ehq386.
O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019; 139: 1483-92. Doi: 10.1161/CIRCULATIONAHA.118.037184.
Duarte LF, Giugliano RP. Lipoproteina and its significance in cardiovascular disease: a review. JAMA Cardiol. 2022; 7: 760-9. Doi: 10.1001/jamacardio.2022.0987.
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021; 37: 1129-50. Doi: 10.1016/j.cjca.2021.03.016.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology ESC. and European Atherosclerosis Society EAS. Eur Heart J. 2020; 41: 111-88. Doi: 10.1093/eurheartj/ehz455.
Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019; 13: 374-92. Doi: 10.1016/j.jacl.2019.04.010.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376: 1713-22. Doi: 10.1056/NEJMoa1615664.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379: 2097-107. Doi: 10.1056/NEJMoa1801174.
Downloads
Published
Versions
- 2024-02-22 (5)
- 2023-06-30 (4)
- 2023-11-29 (3)
- 2023-11-22 (2)
- 2023-06-30 (1)
Issue
Section
License
Copyright (c) 2023 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
